Pfizer Inc. has decided to call it quits in early neuroscience R&D in a move that analysts say was predictable and still leaves open the option of M&A as a return route if other players make a success of it.
Pfizer Jan. 5 said it was ending its neuroscience discovery and early development efforts and re-allocate funding to those areas...








